Skip to main content
Top
Published in: Diabetologia 10/2005

01-10-2005 | Article

The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity

Authors: J. L. Sánchez-Quesada, S. Benítez, A. Pérez, A. M. Wagner, M. Rigla, G. Carreras, L. Vila, M. Camacho, R. Arcelus, J. Ordóñez-Llanos

Published in: Diabetologia | Issue 10/2005

Login to get access

Abstract

Aims/hypothesis

Chemical and biological characteristics of LDL(−) from type 1 diabetic subjects were analysed. The diabetic patients were studied during poor and optimised glycaemic control.

Materials and methods

Total LDL was subfractionated into electropositive LDL(+) and electronegative LDL(−) by anion exchange chromatography and the lipid and protein composition of the two determined.

Results

LDL(−) differed from LDL(+) in that it had higher triglyceride, non-esterified fatty acids, apoE, apoC-III and platelet-activating factor acetylhydrolase (PAF-AH), as well as lower apoB relative content. No evidence of increased oxidation was observed in LDL(−). LDL(−) increased two-fold the release of interleukin 8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) in endothelial cells, suggesting an inflammatory role. Optimisation of glycaemic control after insulin therapy decreased the proportion of LDL(−), but did not modify the composition of LDL subfractions, except for a decrease in PAF-AH activity in LDL(−). The possibility that LDL(−) could be generated by non-enzymatic glycosylation was studied. Fructosamine and glycated LDL content in LDL subfractions from type 1 diabetic patients was greater than in LDL subfractions isolated from normoglycaemic subjects, and decreased after glycaemic optimisation in both subfractions. However, no difference was observed between LDL(+) and LDL(−) before and after insulin therapy.

Conclusions/interpretation

These results provide evidence that LDL(−) is not produced by glycosylation. Nevertheless, LDL(−) from diabetic patients displays inflammatory potential reflected by the induction of chemokine release in endothelial cells. This proatherogenic effect could be related to the high PAF-AH activity in LDL(−).
Literature
1.
go back to reference The DCCT Research Group (1992) Lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial (DCCT) experience. Diabetes Care 15:886–894 The DCCT Research Group (1992) Lipid and lipoprotein levels in patients with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial (DCCT) experience. Diabetes Care 15:886–894
2.
go back to reference Assmann G, Schulte H (1988) The prospective cardiovascular Munster (PROCAM) study. Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116:1713–1724CrossRefPubMed Assmann G, Schulte H (1988) The prospective cardiovascular Munster (PROCAM) study. Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116:1713–1724CrossRefPubMed
3.
go back to reference Navab M, Berliner JA, Watson AD et al (1996) The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16:831–842PubMed Navab M, Berliner JA, Watson AD et al (1996) The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16:831–842PubMed
4.
go back to reference Scheffer PG, Henry RMA, Wever EJM et al (2004) LDL oxidative modifications in well- or moderately controlled type 2 diabetes. Diabetes/Metab Res Rev 20:298–304 Scheffer PG, Henry RMA, Wever EJM et al (2004) LDL oxidative modifications in well- or moderately controlled type 2 diabetes. Diabetes/Metab Res Rev 20:298–304
5.
go back to reference Kim HJ, Kurup IV (1982) Nonenzymatic glycosylation of human low density lipoprotein; evidence for in vivo and in vitro glycosylation. Metabolism 31:348–352CrossRefPubMed Kim HJ, Kurup IV (1982) Nonenzymatic glycosylation of human low density lipoprotein; evidence for in vivo and in vitro glycosylation. Metabolism 31:348–352CrossRefPubMed
6.
go back to reference Sobenin IA, Tertov VV, Koschinski T et al (1993) Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 100:41–54CrossRefPubMed Sobenin IA, Tertov VV, Koschinski T et al (1993) Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 100:41–54CrossRefPubMed
7.
go back to reference Caixàs A, Ordóñez-Llanos J, de Leiva A, Payés A, Homs R, Pérez A (1997) Improvement of glycemic control in diabetes decreases the atherogenic small dense LDL particles. Diabetes 46:1207–1213PubMed Caixàs A, Ordóñez-Llanos J, de Leiva A, Payés A, Homs R, Pérez A (1997) Improvement of glycemic control in diabetes decreases the atherogenic small dense LDL particles. Diabetes 46:1207–1213PubMed
8.
go back to reference Avogaro P, Bittolo-Bon G, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8:79–87PubMed Avogaro P, Bittolo-Bon G, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8:79–87PubMed
9.
go back to reference Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J (2004) Electronegative low-density lipoprotein. Curr Opin Lipidol 15:329–335CrossRefPubMed Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J (2004) Electronegative low-density lipoprotein. Curr Opin Lipidol 15:329–335CrossRefPubMed
10.
go back to reference Sánchez-Quesada JL, Benítez S, Franco M, Otal C, Blanco-Vaca F, Ordóñez-Llanos J (2002) Density distribution of electronegative LDL (LDL(−)) in normolipemic and hyperlipemic subjects. J Lipid Res 43:699–705PubMed Sánchez-Quesada JL, Benítez S, Franco M, Otal C, Blanco-Vaca F, Ordóñez-Llanos J (2002) Density distribution of electronegative LDL (LDL(−)) in normolipemic and hyperlipemic subjects. J Lipid Res 43:699–705PubMed
11.
go back to reference Benítez S, Ordóñez-Llanos, Franco M et al (2004) Effect of simvastatin in familial hypercholesterolemia on the affinity of charge-differing low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol 93:414–420CrossRefPubMed Benítez S, Ordóñez-Llanos, Franco M et al (2004) Effect of simvastatin in familial hypercholesterolemia on the affinity of charge-differing low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol 93:414–420CrossRefPubMed
12.
go back to reference Hodis HN, Kramsch DM, Avogaro P et al (1994) Biochemical and cytotoxic characteristics of an in vivo circulating oxidised low-density lipoprotein (electronegative LDL). J Lipid Res 35:669–677PubMed Hodis HN, Kramsch DM, Avogaro P et al (1994) Biochemical and cytotoxic characteristics of an in vivo circulating oxidised low-density lipoprotein (electronegative LDL). J Lipid Res 35:669–677PubMed
13.
go back to reference Demuth K, Myara I, Chappey B et al (1996) A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 16:773–783PubMed Demuth K, Myara I, Chappey B et al (1996) A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 16:773–783PubMed
14.
go back to reference Chen CH, Jiang T, Yang JH et al (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107:2102–2108CrossRefPubMed Chen CH, Jiang T, Yang JH et al (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107:2102–2108CrossRefPubMed
15.
go back to reference de Castellarnau C, Sánchez-Quesada JL, Benítez S et al (2000) Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 20:2281–2287PubMed de Castellarnau C, Sánchez-Quesada JL, Benítez S et al (2000) Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 20:2281–2287PubMed
16.
go back to reference Sánchez-Quesada JL, Camacho M, Antón R, Benítez S, Vila L, Ordóñez-Llanos J (2003) Electronegative LDL of FH subjects. Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166:261–270CrossRefPubMed Sánchez-Quesada JL, Camacho M, Antón R, Benítez S, Vila L, Ordóñez-Llanos J (2003) Electronegative LDL of FH subjects. Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 166:261–270CrossRefPubMed
17.
go back to reference Ziouzenkova O, Asatryan L, Sahady D et al (2003) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 278:39874–39881CrossRefPubMed Ziouzenkova O, Asatryan L, Sahady D et al (2003) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 278:39874–39881CrossRefPubMed
18.
go back to reference Sánchez-Quesada JL, Otal-Entraigas C, Franco M et al (1999) Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with familial hypercholesterolemia. Am J Cardiol 84:655–659CrossRefPubMed Sánchez-Quesada JL, Otal-Entraigas C, Franco M et al (1999) Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with familial hypercholesterolemia. Am J Cardiol 84:655–659CrossRefPubMed
19.
go back to reference Ziouzenkova O, Asatryan L, Akmal M et al (1999) Oxidative cross-linking of apoB100 and hemoglobin results in low density lipoproteins modification in blood. J Biol Chem 27:18916–18924CrossRef Ziouzenkova O, Asatryan L, Akmal M et al (1999) Oxidative cross-linking of apoB100 and hemoglobin results in low density lipoproteins modification in blood. J Biol Chem 27:18916–18924CrossRef
20.
go back to reference Sánchez-Quesada JL, Pérez A, Caixàs A et al (1996) Electronegative low-density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 39:1469–1476CrossRefPubMed Sánchez-Quesada JL, Pérez A, Caixàs A et al (1996) Electronegative low-density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 39:1469–1476CrossRefPubMed
21.
go back to reference Sánchez-Quesada JL, Pérez A, Caixàs A et al (2001) Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 86:3243–3249CrossRefPubMed Sánchez-Quesada JL, Pérez A, Caixàs A et al (2001) Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 86:3243–3249CrossRefPubMed
22.
go back to reference Moro E, Zambón C, Pianetti S, Cazzolato G, Pais M, Bittolo Bon G (1998) Electronegative low density lipoprotein subform is increased in type 2 (non-insulin-dependent) microalbuminuric patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 35:161–164CrossRefPubMed Moro E, Zambón C, Pianetti S, Cazzolato G, Pais M, Bittolo Bon G (1998) Electronegative low density lipoprotein subform is increased in type 2 (non-insulin-dependent) microalbuminuric patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 35:161–164CrossRefPubMed
23.
go back to reference Moro E, Alessandrini P, Zambón C et al (1999) Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16:663–669CrossRefPubMed Moro E, Alessandrini P, Zambón C et al (1999) Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 16:663–669CrossRefPubMed
24.
go back to reference National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057 National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057
25.
go back to reference Sánchez-Quesada JL, Ortega H, Payés-Romero A et al (1997) LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 132:207–213CrossRefPubMed Sánchez-Quesada JL, Ortega H, Payés-Romero A et al (1997) LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. Atherosclerosis 132:207–213CrossRefPubMed
26.
go back to reference Fukunaga K, Suzuki T, Takama K (1993) Highly sensitive high-performance liquid chromatography for the measurement of malondialdehyde in biological samples. J Chromatogr 621:77–81PubMed Fukunaga K, Suzuki T, Takama K (1993) Highly sensitive high-performance liquid chromatography for the measurement of malondialdehyde in biological samples. J Chromatogr 621:77–81PubMed
27.
go back to reference Khoo J, Miller E, McLaughlin P, Steinberg D (1988) Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis 8:348–358PubMed Khoo J, Miller E, McLaughlin P, Steinberg D (1988) Enhanced macrophage uptake of low-density lipoprotein after self-aggregation. Arteriosclerosis 8:348–358PubMed
28.
go back to reference Benítez S, Sánchez-Quesada JL, Ribas V et al (2003) Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL subfraction. Circulation 108:92–96CrossRefPubMed Benítez S, Sánchez-Quesada JL, Ribas V et al (2003) Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL subfraction. Circulation 108:92–96CrossRefPubMed
29.
go back to reference Lyons TJ (1991) Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med 8:411–419PubMed Lyons TJ (1991) Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med 8:411–419PubMed
30.
go back to reference Gambino R, Giunti S, Uberti B, Perin PC, Pagano G, Cassader M (2003) LDL electronegativity is enhanced in type 1 diabetes. Diabetes Care 26:2214–2215PubMed Gambino R, Giunti S, Uberti B, Perin PC, Pagano G, Cassader M (2003) LDL electronegativity is enhanced in type 1 diabetes. Diabetes Care 26:2214–2215PubMed
31.
go back to reference Hermann M, Gneimer B (1992) Altered susceptibility to in vitro oxidation of LDL in LDL complexes and LDL aggregates. Arterioscler Thromb 12:1503–1506PubMed Hermann M, Gneimer B (1992) Altered susceptibility to in vitro oxidation of LDL in LDL complexes and LDL aggregates. Arterioscler Thromb 12:1503–1506PubMed
32.
go back to reference Noto H, Hara M, Karasawa K et al (2003) Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23:829–835CrossRefPubMed Noto H, Hara M, Karasawa K et al (2003) Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23:829–835CrossRefPubMed
33.
go back to reference Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF (1996) LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 45:762–767PubMed Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF (1996) LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 45:762–767PubMed
34.
go back to reference Feillet C, Roche B, Tauveron I et al (1998) Susceptibility to oxidation and physicochemical properties of LDL in insulin-dependent diabetics. Atherosclerosis 136:405–407CrossRefPubMed Feillet C, Roche B, Tauveron I et al (1998) Susceptibility to oxidation and physicochemical properties of LDL in insulin-dependent diabetics. Atherosclerosis 136:405–407CrossRefPubMed
35.
go back to reference Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMed Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMed
36.
go back to reference Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W (2004) Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153–1159CrossRefPubMed Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W (2004) Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153–1159CrossRefPubMed
37.
go back to reference Serban M, Tanaseanu C, Kosaka T et al (2002) Significance of platelet-activating factor acetylhydrolase in patients with non-insulin dependent (type 2) diabetes mellitus. J Cell Mol Med 6:643–647PubMed Serban M, Tanaseanu C, Kosaka T et al (2002) Significance of platelet-activating factor acetylhydrolase in patients with non-insulin dependent (type 2) diabetes mellitus. J Cell Mol Med 6:643–647PubMed
38.
go back to reference Scholin A, Siegbahn A, Lind L et al (2004) CRP and IL-6 concentrations are associated with poor glycemic control despite preserved B-cell function during the first year after diagnosis of type 1 diabetes. Diabetes/Metab Res Rev 20:205–210 Scholin A, Siegbahn A, Lind L et al (2004) CRP and IL-6 concentrations are associated with poor glycemic control despite preserved B-cell function during the first year after diagnosis of type 1 diabetes. Diabetes/Metab Res Rev 20:205–210
39.
go back to reference Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M (2004) Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 112:378–382CrossRefPubMed Mangge H, Schauenstein K, Stroedter L, Griesl A, Maerz W, Borkenstein M (2004) Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 112:378–382CrossRefPubMed
Metadata
Title
The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity
Authors
J. L. Sánchez-Quesada
S. Benítez
A. Pérez
A. M. Wagner
M. Rigla
G. Carreras
L. Vila
M. Camacho
R. Arcelus
J. Ordóñez-Llanos
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1899-8

Other articles of this Issue 10/2005

Diabetologia 10/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.